Genetic Testing

Genetic testing is currently available for numerous chronic diseases, including cardiovascular disease, osteoporosis, detoxification impairments, immunological defects neurological and chronic inflammatory conditions. Using gene SNPs (single nucleotide polymorphism) helps identify those physiological risks that are modifiable using diet, nutritional intervention, lifestyle changes and specific pharmacological intervention.

Various different companies offer genetic testing. Here are some of the ones we are currently doing. As this becomes more financially feasible, there will be more added to the list:

BRACCA is the test done to determine high risk for breast and ovarian cancer

COLON Cancer: Colonsentry is done by Innovative Diagnostic Laboratory

Lung Cancer Early CDT lung cancer screening is done by Innovative Diagnostic Labs

MTHFR testing can help with treatment for mental health, neurological diseases and cardiovascular risk.

Assurex GeneSight test is available for testing for pain, psychiatric medications, and ADD medications

Detoxification This test evaluates SNPs associated with increased risk of impaired detoxification capacity especially when exposed to environmental toxins. It also identifies individuals potentially susceptible to adverse drug reactions.

Neurogenomics This test evaluates single nucleotide polymorphisms (SNPs) in genes that modulate methylation, glutathione conjugation, oxidative protection and the potential to evaluate vascular oxidation.

Cardiovascular risk testing can help to identify those patients that have increased genetic risk for heart disease and will need more nutritional support to reduce risk

Apo E (apoliprotein E)
These genes affect how the body processes cholesterol, responds to inflammation, and metabolizes B vitamins. The presence of these SNPs can increase risk of cardiovascular disease, hyperlipidemia, and blood vessel damage.

Estrogen Metabolism Genetics

GST (M1 and P1)
COMT (catechol-O-methyl transferase)
Estrogen metabolism SNPs focus on the Phase 1 enzymes involved in the formation of anti- or procarcinogenic metabolites such as 2-hydroxyestrone and 4-hydroxyestrone, respectively, as well as the Phase 2 enzymes responsible for the subsequent metabolism of these compounds. Levels of the various estrogen metabolites modulate risk of both breast cancer and osteoporosis.


GP3a (Glycoprotein 3)

Factor 2 (Prothrombin)
PAI-1 (Plasminogen activator inhibitor-1)
Factor 5 (Leiden)
These genetic variants focus on estrogen’s interaction with some of the key constituents of the clot formation and fibrinolysis process, such as clotting factors and inhibitors of fibrinolysis. The SNPs can over-activate blood clotting processes, increasing the risk of sudden cardiac events such as thrombosis, heart attacks, and strokes, especially among women take supplemental estrogens and oral contraceptives.



Osteoporosis SNPs relate to estrogens influence on inflammation, bone resorption, vitamin D function and bone collagen formation.